These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32602809)

  • 1. Small-molecule inhibitors of α-synuclein for the treatment of Parkinson's disease: a patent landscape.
    Joubert J
    Pharm Pat Anal; 2020 May; 9(3):63-65. PubMed ID: 32602809
    [No Abstract]   [Full Text] [Related]  

  • 2. The hexapeptide PGVTAV suppresses neurotoxicity of human α-synuclein aggregates.
    Choi MY; Kim YS; Lim D; Kang SJ; Kim YH; Lee K; Im H
    Biochem Biophys Res Commun; 2011 May; 408(2):334-8. PubMed ID: 21510923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-synuclein and iron: two keys unlocking Parkinson's disease.
    Lingor P; Carboni E; Koch JC
    J Neural Transm (Vienna); 2017 Aug; 124(8):973-981. PubMed ID: 28168622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-synuclein assembly as a therapeutic target of Parkinson's disease and related disorders.
    Ono K; Hirohata M; Yamada M
    Curr Pharm Des; 2008; 14(30):3247-66. PubMed ID: 19075704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders.
    Amer DA; Irvine GB; El-Agnaf OM
    Exp Brain Res; 2006 Aug; 173(2):223-33. PubMed ID: 16733698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. α-Synuclein ubiquitination and novel therapeutic targets for Parkinson's disease.
    Rott R; Szargel R; Shani V; Bisharat S; Engelender S
    CNS Neurol Disord Drug Targets; 2014; 13(4):630-7. PubMed ID: 24168368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-synuclein oligomers: a new hope.
    Bengoa-Vergniory N; Roberts RF; Wade-Martins R; Alegre-Abarrategui J
    Acta Neuropathol; 2017 Dec; 134(6):819-838. PubMed ID: 28803412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of α-synuclein fibrillization by ring-fused 2-pyridones: templation and inhibition involve oligomers with different structure.
    Horvath I; Sellstedt M; Weise C; Nordvall LM; Krishna Prasad G; Olofsson A; Larsson G; Almqvist F; Wittung-Stafshede P
    Arch Biochem Biophys; 2013 Apr; 532(2):84-90. PubMed ID: 23399432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the Pathogenesis Involved in Parkinson's Disease and Potential Therapeutic Treatment Strategies.
    Dhanawat M; Mehta DK; Gupta S; Das R
    Cent Nerv Syst Agents Med Chem; 2020; 20(2):88-102. PubMed ID: 32628600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cell-based model of alpha-synucleinopathy for screening compounds with therapeutic potential of Parkinson's disease.
    Zhao DL; Zou LB; Zhou LF; Zhu P; Zhu HB
    Acta Pharmacol Sin; 2007 May; 28(5):616-26. PubMed ID: 17439717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule-mediated stabilization of vesicle-associated helical α-synuclein inhibits pathogenic misfolding and aggregation.
    Fonseca-Ornelas L; Eisbach SE; Paulat M; Giller K; Fernández CO; Outeiro TF; Becker S; Zweckstetter M
    Nat Commun; 2014 Dec; 5():5857. PubMed ID: 25524885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease.
    Török N; Majláth Z; Szalárdy L; Vécsei L
    Expert Opin Investig Drugs; 2016 Nov; 25(11):1281-1294. PubMed ID: 27677932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activating Autophagy as a Therapeutic Strategy for Parkinson's Disease.
    Fowler AJ; Moussa CE
    CNS Drugs; 2018 Jan; 32(1):1-11. PubMed ID: 29492779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's Disease: Alpha Synuclein, Heme Oxygenase and Biotherapeutic Countermeasures.
    Haines DD; Trushin MV; Rose S; Bernard IAS; Mahmoud FF
    Curr Pharm Des; 2018; 24(20):2317-2321. PubMed ID: 30019639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease.
    Drouin-Ouellet J; St-Amour I; Saint-Pierre M; Lamontagne-Proulx J; Kriz J; Barker RA; Cicchetti F
    Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25522431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. beta-Sheet-breaking peptides inhibit the fibrillation of human alpha-synuclein.
    Kim YS; Lim D; Kim JY; Kang SJ; Kim YH; Im H
    Biochem Biophys Res Commun; 2009 Oct; 387(4):682-7. PubMed ID: 19622344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zeroing in on neurodegenerative α-synuclein.
    Kingwell K
    Nat Rev Drug Discov; 2017 May; 16(6):371-373. PubMed ID: 28559555
    [No Abstract]   [Full Text] [Related]  

  • 18. α-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinson's disease.
    Singh SK; Dutta A; Modi G
    Future Med Chem; 2017 Jun; 9(10):1039-1053. PubMed ID: 28632413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. alpha-Synuclein: a therapeutic target for Parkinson's disease?
    Maguire-Zeiss KA
    Pharmacol Res; 2008; 58(5-6):271-80. PubMed ID: 18840530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons.
    Pujols J; Peña-Díaz S; Lázaro DF; Peccati F; Pinheiro F; González D; Carija A; Navarro S; Conde-Giménez M; García J; Guardiola S; Giralt E; Salvatella X; Sancho J; Sodupe M; Outeiro TF; Dalfó E; Ventura S
    Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10481-10486. PubMed ID: 30249646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.